Shares of electroCore, Inc. (NASDAQ:ECOR – Get Free Report) have earned a consensus recommendation of “Hold” from the five brokerages that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $22.00.
A number of research firms recently weighed in on ECOR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of electroCore in a report on Monday, December 29th. Wall Street Zen upgraded shares of electroCore from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. HC Wainwright decreased their price target on shares of electroCore from $25.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, January 26th. Zacks Research lowered electroCore from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 28th. Finally, Brookline Capital Acquisition upgraded electroCore to a “strong-buy” rating in a research report on Tuesday, February 3rd.
Read Our Latest Analysis on ECOR
Institutional Investors Weigh In On electroCore
electroCore Stock Down 2.1%
ECOR stock opened at $7.58 on Monday. The firm has a market capitalization of $60.64 million, a PE ratio of -4.43 and a beta of 0.48. electroCore has a twelve month low of $4.16 and a twelve month high of $16.18. The stock has a 50-day simple moving average of $6.02 and a two-hundred day simple moving average of $5.40.
electroCore Company Profile
electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.
The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.
See Also
- Five stocks we like better than electroCore
- Silver Crossed $100: Is the $500 surge next? (Join us March 4)
- America’s 1776 happening again
- Unlocked: Elon Musk’s Next Big IPO
- Silver paying 20% dividend. Plus 68% share gains
- REVEALED: Something Big Happening Behind White House Doors
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
